Organogenesis Holdings Inc

ORGO remains in a sustained downtrend on both medium- and long-term horizons, trading below all key moving averages with no active bullish patterns. Medium-term bias is bearish given persistent lower highs and lows and resistance at the 21/50 EMA zone. Short-term execution readiness is confirmed by a failed rally into the EMAs and rejection at moving-average resistance. Sell Now is advised at these resistance levels into the ongoing downtrend.

• ↑FDA acceptance of ReNu BLA could expand knee osteoarthritis treatment market
• ↑Restructuring plan targets $14M in annual cost savings to boost margins
• ↓Q1 net product revenue plunged 58% YoY to $36.3M, driven by a 63% drop in wound care sales